The panacea for cardiovascular diseases: The role of statins in the management of heart failure

International Journal of Cardiology

Volumn 129, Issue 3, 2008, Pages 422-423

  Celik, Turgay ^a   Iyisoy, Atila ^a   Yuksel, U Cagdas ^b   Isik, Ersoy ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b Sarikamis Army District Hospital Turkey   (Turkey)

Author keywords

Cardiovascular mortality; Chronic heart failure; Statins

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTOXIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; LIPOPROTEIN; MEVALONIC ACID; UBIQUINONE; VALSARTAN;

ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CIRCULATION; CONGESTIVE CARDIOMYOPATHY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPOTENSION; INFLAMMATION; LIPID OXIDATION; MITOCHONDRIAL MEMBRANE; MORTALITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETROSPECTIVE STUDY; SURVIVAL; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME; ANIMAL; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; ENZYMOLOGY; HEART FAILURE;

ANIMALS; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 52949149633     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.06.045     Document Type: Article

References (18)

1. Krum H., Latini R., Maggioni A.P., et al. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol 119 1 (2007) 48-53
2. Lipinski M.J., Abbate A., Fuster V., and Vetrovec G.W. Drug insight: statins for nonischemic heart failure-evidence and potential mechanisms. Nat Clin Pract Cardiovasc Med 4 (2007) 196-205
3. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101 (1998) 2711-2719
4. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
5. Oi S., Haneda T., Osaki J., et al. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol 376 (1999) 139-148
6. Luo J.D., Zhang W.W., Zhang G.P., Guan J.X., and Chen X. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol 26 (1999) 903-908
7. Bellosta S., Via D., Canavesi M., et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18 (1998) 1671-1678
8. Nickenig G., Baumer A.T., Temur Y., Kebben D., Jockenhovel F., and Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 100 (1999) 2131-2134
9. Node K., Fujita M., Kitakaze M., Hori M., and Liao J.K. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 (2003) 839-843
10. Laufs U., Wassmann S., Schackmann S., Heeschen C., Bohm M., and Nickenig G. Beneficial effects of statins in patients with non-ischemic heart failure. Z Kardiol 93 (2004) 103-108
11. Tousoulis D., Antoniades C., Bosinakou E., et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 178 (2005) 359-363
12. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
13. Rauchova H., Drahota Z., and Lenaz G. Function of coenzyme Q in the cell: some biochemical and physiological properties. Physiol Res 44 (1995) 209-216
14. Watts G.F., Castelluccio C., Rice-Evans C., Taub N.A., Baum H., and Quinn P.J. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 46 (1993) 1055-1057
15. Krum H., and McMurray J.J. Statins and chronic heart failure: do we need a large-scale outcome trial?. J Am Coll Cardiol 39 (2002) 1567-1573
16. Sander S., Coleman C.I., Patel A.A., Kluger J., and White C.M. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail 12 (2006) 464-472
17. Rauchhaus M., Coats A.J., and Anker S.D. The endotoxin-lipoprotein hypothesis. Lancet 356 (2000) 930-933
18. Christ M., Klima T., Grimm W., Mueller H.H., and Maisch B. Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy. Eur Heart J 27 (2006) 691-699